
FDA adviser resigns over approval of new Alzheimer's drug
CNN
A member of an FDA advisory committee said Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.
The FDA approved aducanumab, to be sold under the brand name Aduhelm, this week over the objections of its advisory Peripheral and Central Nervous System Drugs Advisory Committee. Mayo Clinic neurologist Dr. David Knopman told CNN Wednesday he had resigned from the committee in protest.More Related News







